Heart valve damage

Heart valve damage (also called valvulopathy or cardiac valvulopathy) is a condition in which the leaflets of one or more heart valves become thickened and scarred, preventing them from sealing cleanly, so that blood leaks backward through the valve with each heartbeat.

The established pharmacological mechanism is sustained activation of the serotonin 2B receptor (5-HT₂B), which is expressed on the fibroblast cells of cardiac valve tissue. Chronic stimulation of this receptor drives abnormal connective tissue growth, progressively stiffening the leaflets over months to years.

The most clearly documented cases involve withdrawn appetite suppressants such as fenfluramine and dexfenfluramine, and prolonged therapeutic use of ergot-derived medications. These are potent, persistent 5-HT₂B agonists. The valve changes they produced were measurable by cardiac ultrasound and in some cases required surgical repair.

How it is done

The fibrotic process unfolds over months to years of sustained 5-HT₂B stimulation. Valve leaflets accumulate abnormal connective tissue, becoming thicker and less pliable; the mitral and aortic valves are most commonly affected. Regurgitation — the backward leak — is often mild and asymptomatic in its early stages, which is why it can go undetected without imaging.

The standard detection method is echocardiography: cardiac ultrasound that visualises leaflet anatomy and measures the degree of regurgitation. This is how fenfluramine's cardiac profile was identified during post-market surveillance, and how ergot medications are monitored in clinical practice.

Screening is most relevant when someone has used a confirmed potent 5-HT₂B agonist over an extended period. A baseline echocardiogram establishes whether damage is already present; serial imaging over time can track whether it is progressing.

When it matters

When regurgitation progresses from mild to moderate or severe, the heart chambers begin to compensate by expanding to handle the extra volume — a process that eventually strains the myocardium. At this stage the situation becomes time-sensitive: progressive chamber enlargement can lead to irreversible dysfunction if the valve problem is not addressed.

There is no pharmacological reversal of established leaflet fibrosis. Severe valvulopathy is managed through close cardiac monitoring and, when the valve fails to function adequately, through surgical repair or replacement. The transition from subclinical to clinically significant damage can be slow and symptom-free, which is why serial imaging is the only reliable means of tracking it.

What it cannot tell you

An echocardiogram showing no current damage is a snapshot of valve anatomy at one moment, not a guarantee that damage will not develop. It cannot establish whether fibrotic change has begun at a subclinical level that imaging does not yet resolve.

For compounds with weaker or only partial 5-HT₂B activity — including many substances that carry a theoretical concern based on receptor binding profiles — whether clinically significant valvulopathy can develop with long-term human exposure is genuinely unknown.

The potency threshold, cumulative exposure, and duration required to drive measurable fibrosis have not been established for most such compounds. The mechanistic concern is real; it has not been translated into clinical evidence at lower levels of receptor engagement.

A reassuring scan after short-term or infrequent use does not close this question. Chronic-exposure data for most compounds in this category do not exist.